Patient advocacy groups should help support research

I was a medical researcher for several decades, investigating an unusual, but not rare, condition called infective endocarditis. I found the disease fascinating, primarily because of how understanding it could unlock many secrets of the endothelial cell, the cells lining all our blood vessels. I chose my research subject because it interested me and I thought I could do some good studying it. This is the case for most medical researchers.

Of course, there are incentives nudging researchers toward working on a particular disease. The main one is research funding. Most of my work was funded either by the National Institutes of Health or the American Heart Association. Both organizations, and others like them, from time to time issue invitations to apply for funding in a particular area, one identified by the organization as being in particular need of special support.

In general, though, the approach has been to let researchers propose to these organizations projects of interest to the investigators and let the funding committees choose the best among them. Directed research, telling investigators what to work on, has been viewed with suspicion; it is best to let smart people work on whatever they think best.

There are good reasons why this is a good default position. Very, very often directed research doesn’t get us answers because the answers often come from unexpected places. I can think of many examples where breakthroughs in understanding a particular disease came from research that, at first blush, seemed totally unrelated to it.

However, a problem with this paradigm is that, if no directed research happens, rare and unusual conditions may remain completely mysterious for years, maybe forever, because no medical researcher happens to be interested in them. Patient advocacy groups have an important role to play in such situations.

There’s an interesting example in a recent New England Journal of Medicine of the potential power of these groups. The articles concern a very rare disorder called lymphangioleiomyomatosis, a devastating disease that can strike young women. Because it is so rare, it attracted little attention from medical researchers. Then a mother of a woman with the disease started a patient advocacy group and founded the LAM Foundation. Her tireless efforts attracted some interest, and the money the foundation offered to researchers served as seed money for them to develop grant funding proposals to organizations and agencies with deeper pockets. The LAM Foundation served as a kind of venture capitalist for the research effort. The result of this has been significant strides not only understanding this disease, but useful treatments, too.

I think the other important point to take from this example is that patient advocacy groups should aim to spend most of their precious resources, not on advertising and organizational structure (a chronic pitfall for nonprofits), but on actual research support undertaken on the advice of experts.

Christopher Johnson is a pediatric intensive care physician and author of Your Critically Ill Child: Life and Death Choices Parents Must Face, How to Talk to Your Child’s Doctor: A Handbook for Parents, and How Your Child Heals: An Inside Look At Common Childhood Ailments.  He blogs at his self-titled site, Christopher Johnson, MD.

Comments are moderated before they are published. Please read the comment policy.

  • OSR NK

    I think its a great website, well done.
    I talk abput same type of things at:
    http://www.fitbase.blogspot.com

  • Anonymous

    Thanks Dr. Chris for this timely reminder to patient advocacy groups. The LAM story is a great example. But it’s not just rare diseases that are problematic  – it’s gender balance. 

    For decades, cardiac research has been done largely on (white, middle-aged) men, with women included in statistically insignificant numbers, or excluded entirely.  This, happily, is changing, but the truth is that women are still not lining up to participate in research on their #1 killer.

    The University of Toronto cardiologist Dr. Wendy Tsang, for example, found that although women comprise 53% of patients
    with cardiovascular disease, in clinical trials they represented only
    29% of subjects with coronary artery disease, 25% with heart failure, and 34% with cardiac arrhythmias.

    But interestingly, she found that women
    represented 61% of the subjects in heart disease prevention trials.

    Women do participate in hormone and breast cancer trials – we need to model that acceptance for cardiac research, too.

Most Popular